Posted by Michael Wonder on 09 Aug 2021
Version 4 and counting
9 August 2021 - The Department of Health has published yet another revised agenda for the November 2021 PBAC meeting.
Version notes the addition of a (late?) submission from BMS for nivolumab for the treatment of patients with non-HER2 positive gastric cancer, gastro-esophageal junction cancer or oesophageal adenocarcinoma.
